天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.

ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Struktur
CAS-Nr.
Englisch Name:
ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
Synonyma:
ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
CBNumber:
CB35774730
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Eigenschaften

Sicherheit

ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Chemische Eigenschaften,Einsatz,Produktion Methoden

ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 3)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Hangzhou Yuxin Biotechnology Co., Ltd. --
 haoxinbio@163.com CHINA 6595 58
Xiamen Research Biotechnology Co., Ltd. --
 1562893815@qq.com CHINA 6936 58
Xiamen Huijia Biological Technology Co., Ltd. --
 CHINA 6973 58
  • ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
Copyright 2019 ? ChemicalBook. All rights reserved